Literature DB >> 23556056

Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report.

Min Su Kim1, Young-Joo Jin, Jin-Woo Lee, Jung-Il Lee, Young Soo Kim, Sun Young Lee, Myoung Hun Chae.   

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common malignant disease worldwide, and curative treatment remains difficult because the majority of cases are diagnosed in the advanced stage. Sorafenib is the only known effective systemic treatment, but patients rarely achieve complete remission (CR). A 66-year-old man with a history of alcoholic liver cirrhosis with a diagnosis of advanced HCC, was initially treated with transarterial chemoembolization on four occasions. However, the disease progressed with portal vein thrombosis. Therefore, sorafenib was started, and 4 mo later, the patient achieved CR. The treatment was continued for 12 mo, and CR was maintained up to 4 mo after sorafenib discontinuation.

Entities:  

Keywords:  Complete remission; Hepatocellular carcinoma; Portal vein thrombosis; Sorafenib

Year:  2013        PMID: 23556056      PMCID: PMC3613770          DOI: 10.4251/wjgo.v5.i2.38

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  22 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

Review 2.  Angiogenesis and hepatocellular carcinoma.

Authors:  David Semela; Jean-François Dufour
Journal:  J Hepatol       Date:  2004-11       Impact factor: 25.083

3.  Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma.

Authors:  Marialuisa Novi; Ernesto C Lauritano; Anna C Piscaglia; Brunella Barbaro; Maria A Zocco; Maurizio Pompili; Antonio Gasbarrini
Journal:  Am J Gastroenterol       Date:  2009-05-05       Impact factor: 10.864

4.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

5.  Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.

Authors:  Tadashi Inuzuka; Hiroki Nishikawa; Akira Sekikawa; Haruhiko Takeda; Shinichiro Henmi; Azusa Sakamoto; Sumio Saito; Ryuichi Kita; Toru Kimura; Yukio Osaki; Masatoshi Kudo
Journal:  Oncology       Date:  2011-12-22       Impact factor: 2.935

6.  Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival.

Authors:  E Villa; A Moles; I Ferretti; P Buttafoco; A Grottola; M Del Buono; M De Santis; F Manenti
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

7.  Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.

Authors:  Sean Xiang Wang; Abigail Byrnes; Sadhna Verma; John R Pancoast; Olivier Rixe
Journal:  Target Oncol       Date:  2010-03-23       Impact factor: 4.493

8.  Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report.

Authors:  Leonidas Chelis; Napoleon Ntinos; Vasilios Souftas; Savas Deftereos; Nikolaos Xenidis; Elen Chamalidou; Eustratios Maltezos; Stylianos Kakolyris
Journal:  Med Oncol       Date:  2010-08-31       Impact factor: 3.064

9.  Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis.

Authors:  Mi Sung Park; Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang Hyub Han; Chae Yoon Chon; Jinsil Seong
Journal:  Cancer Chemother Pharmacol       Date:  2012-10-19       Impact factor: 3.333

Review 10.  Managing side effects of angiogenesis inhibitors in renal cell carcinoma.

Authors:  Viktor Grünwald; Hans Heinzer; Walter Fiedler
Journal:  Onkologie       Date:  2007-09-21
View more
  9 in total

1.  Long-term follow-up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report.

Authors:  Jung Gil Park; Won Young Tak; Soo Young Park; Young Oh Kweon; Se Young Jang; Soo Hyun Lee; Yu Rim Lee; Sun Kyung Jang; Keun Hur; Heon Ju Lee
Journal:  Oncol Lett       Date:  2017-08-22       Impact factor: 2.967

2.  Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.

Authors:  Jung Gil Park; Soo Young Park; Hye Won Lee
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

3.  Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.

Authors:  Jia-Yan Ni; Hong-Liang Sun; Yao-Ting Chen; Jiang-Hong Luo; Dong Chen; Xiong-Ying Jiang; Lin-Feng Xu
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

4.  Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib.

Authors:  Akihiro Yamasaki; Narihiro Umeno; Shigeru Harada; Kosuke Tanaka; Masaki Kato; Kazuhiro Kotoh
Journal:  J Gastrointest Oncol       Date:  2016-06

5.  Long-Term Maintenance of Complete Response after Sorafenib Treatment for Multiple Lung Metastases from Hepatocellular Carcinoma.

Authors:  Eisuke Katafuchi; Yuko Takami; Yoshiyuki Wada; Masaki Tateishi; Tomoki Ryu; Kazuhiro Mikagi; Hideki Saitsu
Journal:  Case Rep Gastroenterol       Date:  2015-08-06

Review 6.  Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.

Authors:  Daizhong Liu; Aixiang Liu; Junping Peng; Yong Hu; Xielin Feng
Journal:  Eur J Med Res       Date:  2015-02-04       Impact factor: 2.175

Review 7.  Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review.

Authors:  Tae Suk Kim; Ji Hoon Kim; Baek Hui Kim; Young-Sun Lee; Yang Jae Yoo; Seong Hee Kang; Sang-June Suh; Young Kul Jung; Yeon Seok Seo; Hyung Joon Yim; Jong Eun Yeon; Kwan Soo Byun
Journal:  Clin Mol Hepatol       Date:  2017-06-20

8.  Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.

Authors:  Jung Gil Park
Journal:  Clin Mol Hepatol       Date:  2015-09-30

Review 9.  Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): A case report and literature review.

Authors:  Dong Hyun Kim; Eunae Cho; Sung Bum Cho; Sung Kyu Choi; Sunmin Kim; Jieun Yu; Young-Il Koh; Da Woon Sim; Chung Hwan Jun
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.